Peroxisome proliferator-activated receptor-γPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project
暂无分享,去创建一个
[1] T. Willson,et al. The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.
[2] S. Haffner,et al. The Homeostasis Model in the San Antonio Heart Study , 1997, Diabetes Care.
[3] Johan Auwerx,et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.
[4] Q. Ren,et al. Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. , 2001, The Journal of clinical endocrinology and metabolism.
[5] J. Ranstam,et al. Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes: the Skaraborg Hypertension and Diabetes Project. , 1999, Diabetes, obesity & metabolism.
[6] Eric S. Lander,et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes , 2000, Nature Genetics.
[7] T. Kadowaki,et al. The Pro12Ala Polymorphism in PPAR γ2 May Confer Resistance to Type 2 Diabetes , 2000 .
[8] Julio E. Pérez,et al. Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM , 1997, Diabetes.
[9] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[10] J. Ranstam,et al. Risk factor clustering in patients with hypertension and non‐insulin‐dependent diabetes mellitus. The Skaraborg Hypertension Project , 1998, Journal of internal medicine.
[11] J. Beilby,et al. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. , 2001, European journal of endocrinology.
[12] A. Sugawara,et al. Transcriptional Suppression of Type 1 Angiotensin II Receptor Gene Expression by Peroxisome Proliferator-Activated Receptor-γ in Vascular Smooth Muscle Cells. , 2001, Endocrinology.
[13] M. Kasuga,et al. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. , 2000, Biochemical and biophysical research communications.
[14] V. Colantuoni,et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. , 1999, Diabetes.
[15] F. Collins,et al. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. , 2001, Diabetes.
[16] K. Takeda,et al. Peroxisome Proliferator-Activated Receptor γ Activators Downregulate Angiotensin II Type 1 Receptor in Vascular Smooth Muscle Cells , 2000 .